Archive for the ‘Business’ Category
CLEAR Withdraws Its Endorsement of UK CBD.
CLEAR can no longer endorse or recommend UK CBD as a supplier of CBD products.
This decision is made with regret but is unavoidable due to a number of problems which, despite our best efforts, have proved impossible to resolve. Our endorsement was based on UK CBD’s ethical and quality standards but the position has changed and the directors of UK CBD have been unable satisfactorily to address our concerns.
Our main concern is that certain products marketed by UK CBD contain such high levels of the controlled drugs THC and CBN that we consider them to be unlawful.
One particular product, UK CBD 710 Cannabinoid Crystals, is being promoted as containing “over 4mg of THC”. Anyone importing, supplying or in possession of this product risks criminal prosecution.
Potentially this product could destroy the whole CBD market. If a prosecution was brought under the Psychoactive Substances Act 2016, it could result in all CBD products being regarded as psychoactive.
CLEAR strongly supports the developing CBD market as a legal alternative to high-THC products. However, it is vital for the security of consumers that products comply with the law.
A CLEAR Response To the Liberal Democrats’ Proposals For Cannabis Regulation.
CLEAR welcomes the Liberal Democrats’ proposals which can be seen here. We set out below a few comments which we intend to be constructive.
We represent more than 600,000 people who support cannabis law reform. Our own publication, ‘How to Regulate Cannabis in Britain’ is now in its second edition.
It is based on independent, expert research which we commissioned from the Independent Drug Monitoring Unit, published as ‘Taxing the UK Cannabis Market’.
Comments on ‘A framework for a regulated market for cannabis in the UK’
1. We support a cautious approach and agree that it is better to start with stricter regulation that could, based on experience, be relaxed at a later date if appropriate.
Spectrum of Cannabis Policy
We reject the diagram ‘Exploring a spectrum of options for regulating cannabis’ which paints an inaccurate picture of the effects of a legal market. Evidence from all jurisdictions that have implemented reform does not support the equivalence of ‘social and health harms’ with ‘ultra prohibition’ and ‘commercial production’. It is absolutely clear that legally regulated commercial production is far less harmful than prohibition.
Essentially, instead of a ‘U’ shaped curve, we consider an ‘L’ shaped curve is more accurate.
2. The diagram indicates a fundamental objection to the commercial model implemented in Colorado, Washington and Oregon and the report explicitly rejects the Colorado model in favour of the Uruguay model.
We disagree with this. The Colorado model is a proven success with virtually no downsides. The Uruguay model is still a theory which is yet to be proven in practice. This conclusion in the report is therefore not evidence-based. This suggests that wider political or philosophical considerations have been allowed to trump existing evidence.
3. We are concerned about the undue weight given to restricting commercial enterprise. The UK is not a socialist economy and there is a danger of a ‘nanny-state’ attitude which we cannot support. We repeat the point that it seems wider political or philosophical considerations have been allowed to prevail over actual evidence. There needs to be a balance between a ‘cautious approach’ as in 1. above and over-regulation which will only result in a continuing criminal market. The UK is a market economy and if the legal market is too strict and rigid, the illegal market will flourish.
4. We have very grave concerns about the cannabis social club (CSC) model which provides significant opportunity for the corruption of those involved into major criminal enterprises with exploitation of both workers and customers. The establishment of such ‘clubs’ is entirely unnecessary given the other more controllable methods of supply and will only lead to diversion and perhaps active marketing of excessive production through criminal networks. In other words, CSCs are a golden opportunity for the emergence of ‘drug pushers’ and they undermine the whole purpose of cautious regulation.
5. We regard the recommendation not to permit the production and marketing of ‘edibles’ as an error. If the other recommendations making raw herbal cannabis legally available are implemented then this will inevitably lead to the production and marketing of unregulated ‘edibles’, undermining the whole purpose of regulation. Far better to learn from the mistakes already made in excessively potent ‘edible’ products and introduce appropriate regulations with reduced dosages.
If anything, ‘edibles’ need regulation far more urgently than the raw product because of the potential for very unpleasant overdosing. To abrogate responsibility for this is an extremely unwise proposal and inconsistent with the whole basis for a regulated market.
6. We would encourage a more positive and supportive approach to enable producer countries such as Morocco, the Lebanon, Pakistan and Afghanistan to supply varieties of cannabis resin and hashish. Encouraging such trade under strict regulation will further undermine criminal activity and offers great potential for better relations and positive ‘soft power’ influence on these countries. We recognise the difficulties involved in this with regard to the UN conventions but consider it is a prize worth working towards.
7. For the same reasons set out above we consider that a refusal to regulate concentrates and vapouriser products undermines the whole purpose of a regulated market. Vapouriser products are almost certainly going to be an important component of the medical cannabis market. These nettles must be grasped. To avoid them is irresponsible.
8. We would argue for far more emphasis on harm reduction information, particularly about smoking and avoiding mixing cannabis with tobacco. As in 7. above, we would actively promote the choice of vapouriser products.
9. In principle we agree with the proposal for three levels of THC content and for minimum CBD content. However, there is no evidence to support the necessity for CBD content as high as 4%. The evidence suggests that levels of 1% or 2% adequately meet the desirable ‘entourage’ effects of CBD. Furthermore, at these levels, existing strains are available. Little consideration has been given to the practicalities of developing three new strains to meet the THC:CBD ratios proposed. To develop such strains and ensure they are stable and consistent is the work of several years, requiring significant investment and so undermines the ability to implement these proposals in timely fashion.
10. We consider that the ‘plain packaging’ proposal is unnecessarily restrictive in the UK’s market economy. We agree with child proof containers but would recommend that far more emphasis is given to content and harm reduction labelling. There is nothing to be gained from restricting the marketing and commercial enterprise of companies wishing to develop brands and packaging styles within strict regulations.
11. For reasons already set out we consider that the restrictions on exterior and interior retailer environments are oppressive and will be self-defeating. The UK is not accustomed to such overbearing and anti-business regulation. Existing pharmacies do not operate under such heavy restrictions and they make significant use of point-of-sale and merchandising techniques.
Overall, we welcome this document and the proposals it contains. One final point that is of significance is that clearly there was no ‘consumer’ representation on the panel and this is obvious in some of the tone and detail of the report. We recommend that account should be taken of consumer opinion in any future development of the proposals.
GW Founder And Chairman, Geoffrey Guy, Explains Sativex.
“Most people in our industry said it was impossible to turn cannabis into a prescription medicine. We had to rewrite the rule book. We have the first approval of a plant extract drug in modern history. It has 420 molecules, whereas every other drug has just one.”
Fast Moving Consumer Goods.
Commercialisation Is The Only Sustainable Route To Legalisation.
CLEAR, The British Medicinal Cannabis Campaign and UK CBD Combine To Offer Media Briefings.
The subject of cannabis as medicine is certain to rise to the top of the UK news agenda in forthcoming weeks as a new Coronation Street storyline unfolds.
The character Izzy Armstrong (Cherylee Houston) who has Ehlers-Danlos Syndrome, will be seen suffering when her prescription medicine fails to alleviate her pain. Erica Holroyd (Claire King) will then suggest that she starts using cannabis as an alternative and ends up supplying Izzy with the drug. The programme will look at all aspects of the debate on medicinal cannabis and examine the legal implications and the far reaching consequences of Izzy’s actions for her family.
Now, three of the UK’s most important organisations in the field are joining forces to provide the media with facts, evidence and personal testimonies about medicinal cannabis.
CLEAR is the largest drugs policy reform group in the UK with nearly 600,000 followers. The British Medicinal Cannabis Campaign (BMCC) is an independent group consisting of 4,500 members, all of whom are UK-based medicinal cannabis users. UK CBD is the leading distributor of legal, cannabinoid nutraceuticals including the world famous Charlotte’s Web and Mary’s brands.
Roland Gyallay-Pap, managing director of CLEAR, commented:
“Not for the first time, but at a crucial time in the worldwide debate, the issue of medicinal cannabis will be addressed in a British soap. We have high hopes that this will stimulate the debate and bring the absurdity of the UK government’s position into sharp focus.”
Throughout Europe, the USA, Canada, Australia, Israel and South America, interest in and the use of medicinal cannabis is growing fast. The UK is now virtually isolated amongst first world countries with the stubborn refusal of government even to consider the evidence. However there is a growing clamour from politicians, scientists and doctors that it must address what is a deeply cruel and evidence-free policy. Hundreds of thousands already use medicinal cannabis and risk a criminal record just for trying to improve their health. In addition they have to deal with a criminal underworld and risk violence, contaminated and low quality product all because government refuses to take responsibility.
There is now an overwhelming body of peer-reviewed, scientific evidence on the safety and efficacy of cannabis as medicine. CLEAR published ‘Medicinal Cannabis: The Evidence’ in April 2015 which has received international acclaim and is now also available in a Spanish language edition. Download here in English or Spanish.
Individual briefings will be available on request to journalists, reporters, media organisations and other interested parties. Briefings will be led by Peter Reynolds, one of the nation’s leading experts on the science, medicine and politics of cannabis, Mark Scott, a representative of BMCC and Nicolas Ellis, founder and managing director of UK CBD.
Please contact CLEAR to arrange a briefing at your premises by appointment. Alternatively, a central London venue can be arranged on request.
Expanding Heathrow Is Reckless And Ridiculous.
I find it inconceivable that any sane human being can even consider expansion at Heathrow. The idea of increasing the traffic over what is already a hellhole, already unfit for human habitation, is madness.
The sickening amount of money pumped into the campaign to expand Heathrow raises very unusual feelings in me. It repels me and turns me against business. If this is the result of the profit motive then it is sickening, disgusting and demeans everyone involved.
I think those who advocate expanding Heathrow have slipped into a form of mental illness where common sense is overwhelmed by greed. But I think they’re wrong. It cannot be a wise decision on any basis. The cost is far, far too great.
I’m with Boris and a brand, spanking new mega airport in the Thames Estuary. It is an investment that will enrich our country, that will create so many jobs over so many decades that it can only be a winner. It is the only rational decision.
This Is The Future Of Cannabis. For Medicine, Nutrition And Pleasure.
One of these vape pens contains Blue Dream sativa cannabis oil, 91% THC, the other is Hindu Kush indica cannabis oil, 85% THC and the spare cartridge has the dregs of some New York City Diesel sativa, 85% THC. You can’t tell which is which to look at them but each has a distinctive flavour and effect. They’re not completely odour free but almost.
This is the future of cannabis as a consumer product. It is cleaner, neater, handier, healthier and better for you than raw herbal cannabis. Most importantly, for medicinal applications, it homogenises all the compounds into an oil of consistent quality and content meaning that dosage and effect at last becomes predictable and reliable.
High CBD Oil For Medical Use
I have been investigating this theory for some time but my recent trip to Colorado enabled me to conduct some practical experiments and more thoroughly understand how this idea can work. I am now convinced that this is the way forward for the cannabis industry. Once we achieve legalisation in the UK, which is inevitable, probably in about five years, these pens are how cannabis will become available as a consumer product on the high street. They are also how medicinal cannabis will be dispensed. Your doctor’s prescription will be fulfilled by a cartridge with the appropriate blend of cannabinoids which you screw onto your battery and use immediately. Batteries will also be supplied on prescription, in the same way that syringes or blood glucose meters are for diabetics.
In Colorado dispensaries these pens are already available in a choice of strains and blends. Currently, the popular products contain 250 mg of THC in a blend of cannabis oil and propylene glycol (PG), just as e-cigs contain a nicotine oil and PG.
Alternatively, you can buy the oil of your choice and fill the cartridges yourself. This is undoubtedly the way to do it and a wide choice of oils is available, made by CO2 and solvent extraction processes. The Farm, my favourite dispensary in Boulder, is already supplying cannabinoid blends such as a 60% CBD, 12% THC, 4% CBN product which is clearly for medicinal use. I have no doubt that soon we will see a Charlotte’s Web product and Sativex-like blends with equal ratios of THC:CBD. Other, more sophisticated blends of other cannabinoids and probably terpenes will soon follow.
However, I am certain that some propylene glycol is a good thing. The oil vapes much better when diluted and PG is nothing to worry about, it is in many health, cosmetic and food products. It has many uses. It’s a solvent, humectant (keeps things moist), preservative and it helps absorption of some products. It is non-toxic.
There is further development work to be done. I believe there is a ‘sweet spot’ for the correct amount of PG, probably around 20%. I also think the battery and cartridges can be improved, particularly for medical use. Once this is achieved, a product like this with perhaps a 60:40 THC:CBD ratio should form the basis of an application to the Medicines and Health products Regulatory Agency (MHRA) for a marketing authorisation. It will knock Sativex into a cocked hat. In fact, if GW Pharma aren’t investigating this already then they are failing in their duty to shareholders. I shall certainly be doing all I can to research and facilitate the funding to bring such a product to market.
Yes, this is the future of cannabis. Imagine the packaging, marketing and merchandising opportunities for the recreational market. Understand the overwhelming benefits of this as medicine against the raw, herbal product. Yes, I know some will object and the tired old hippy luddites will say it’s a sell out and many more Big Pharma conspiracy theories will emerge but this is the future. Remember you heard it here first.
It’s Time To Be CLEAR.
The prohibition of cannabis has caused massive harm to our society. It has created a criminal market which has attacked our children, our communities, our health and our liberty. The time to end this failed experiment is now.
Cannabis in West Sussex, England, UK. With acknowledgement and thanks to Joni Mitchell and Eddie Mitchell of Aerial News. (No relation, as far as we know)
I came upon a child of God
He was walking along the road
And I asked him where are you going
And this he told me
I’m going on down to Yasgur’s farm *
I’m going to join in a rock ‘n’ roll band
I’m going to camp out on the land
I’m going to try an’ get my soul freeWe are stardust
We are golden
And we’ve got to get ourselves
Back to the gardenThen can I walk beside you
I have come here to lose the smog
And I feel to be a cog in something turning
Well maybe it is just the time of year
Or maybe it’s the time of man
I don’t know who I am
But you know life is for learningWe are stardust
We are golden
And we’ve got to get ourselves
Back to the gardenBy the time we got to Woodstock
We were half a million strong
And everywhere there was song and celebration
And I dreamed I saw the bombers
Riding shotgun in the sky
And they were turning into butterflies
Above our nationWe are stardust
Billion year old carbon
We are golden
Caught in the devil’s bargain
And we’ve got to get ourselves
back to the garden
© Siquomb Publishing Company
This Is How The UK Government Lies To Its Citizens About Cannabis.
The preposterous response from the UK government to the massive petition for the legalisation of cannabis is a pack of lies.
Systematic Misinformation, Deception And Dishonesty
Yes. Lies. Not a word it’s wise to use unless it’s accurate but in this case it is. The Home Office is disgraced on so many aspects of its work but it has been systematically misleading, misinforming and promoting untruths about cannabis since 1971. Individual Home Secretaries are fully complicit in this dishonesty, most notably James Callaghan, Merlyn Rees, William Whitelaw, Leon Brittan, Douglas Hurd, Michael Howard, Jack Straw, Jacqui Smith, Alan Johnson and the incumbent, Theresa May.
Certainly in the last 20 years there can be no excuse at all. The balance of scientific evidence has been quite clear for at least that long that although a very small number of people may be vulnerable, for 99% of people cannabis is almost completely benign and often beneficial.
The dishonesty of these disgraced ministers brings shame on both the Conservative and Labour parties and the civil service officials in the Home Office. They all know full well that they have lied to the public and they continue to do so, undoubtedly because of corrupt influence from vested interests, principally the tabloid editors, press barons and the alcohol industry. Their lies have resulted in the unnecessary criminalisation of over one million people, the frittering away of tens of billions in futile law enforcement costs and lost tax revenue. Most dreadful of all, the denial of access to medicinal cannabis by those in pain, suffering and disability.
The basis for the government’s dismissal of the petition is given as the Advisory Council on the Misuse of Drugs (ACMD) 2008 report ‘Cannabis: Classification and Public Health’.
In the covering letter to the report, the then chair of the ACMD does say “… the use of cannabis is a significant public health issue. Cannabis can unquestionably cause harm to individuals and society.”
Judge for yourself whether the evidence in the report supports the idea that cannabis is a “significant public health issue”. I don’t think it does and nowhere in the report is such an unequivocal statement made except in the covering letter. Of course it is true that cannabis can cause harm to individuals, just as digestive biscuits, chips and sugary drinks can, so that’s pretty meaningless. There is no evidence in the report at all of cannabis causing harm to society.
But the covering letter then makes the point very strongly that “strategies designed to minimise its use and adverse effects must be predominantly public health ones. Criminal justice measures – irrespective of classification – will have only a limited effect on usage.”
The report recommends that cannabis remain in class C of the Misuse of Drugs Act 1971 but the government of the day, led by Gordon ‘Skunk is Lethal’ Brown, ignored that and increased it to class B.
Read the report yourself. Compare it with the government’s response to the petition. To claim that the report supports present policy is false. It directly contradicts present policy. There is also now a host of high quality evidence on the reality of decriminalised or regulated cannabis markets from the Netherlands, Portugal, Colorado and Washington. This shows beyond any doubt that the government’s suggestions of “drug dependence… misery… increased misuse” have no basis in evidence at all. Furthermore the idea that new tax revenue would be outweighed by new costs is directly contradicted by every study on the subject. I repeat, the government’s response is a pack of lies
Sadly, the United Kingdom is a country where government ministers are prepared to lie, mislead, distort evidence and deceive the British people in order to maintain policies based on prejudice and the corrupt influence of vested interests.
The Man Who Smashed UK Cannabis Prohibition – And Looks Set To Do The Same In America.
Dr Geoffrey Guy
Across social media, it’s ‘on message’ to despise Big Pharma and to promote the idea that government and pharmaceutical companies are engaged in the business of making people ill and feeding them with drugs in the pursuit of profit.
In the cannabis campaign, it’s virtually compulsory to abuse, defame and promote conspiracy theories about GW Pharmaceuticals, the world’s leading developer of cannabis-based medicines.
Now GW Pharma is hardly ‘Big Pharma’. It’s annual revenues for 2014 were £30 million. By contrast, Pfizer’s 2014 revenue was $50 billion. But such trifling facts are of no concern to the keyboard warriors and trolls that plague the cannabis campaign and bring it into disrepute every day.
In any case, I’m not sure whose message this is and why anyone buys into this hate-filled invective and unjust condemnation of an industry that has saved so many lives. Antibiotics, vaccines and, yes, chemotherapy products have saved or extended millions of lives. The most profitable pharmaceutical product of all time, Zantac (ranitidine), cures or prevents stomach ulcers and has prevented millions from having to undergo major surgery. Certainly, as in any industry, there have been mistakes, things have gone wrong and much could be improved but overall, the pharmaceutical industry is a huge force for good in our world.
Those engaged in these bitter, vindictive, online campaigns are largely sheep, ignorant of the facts and simply jumping on another hysterical bandwagon that they understand nothing about. They complain about the pursuit of profit and that money is being made from medicines and healthcare. It’s a strangely socialist and anti-business attitude, particularly as so much of it comes from America, supposedly the home of free enterprise where the maverick and outsider who triumphs against all the odds is usually revered.
Dr Geoffrey Guy, who founded GW Pharmaceuticals in 1998, is such a man. He has broken the UK government’s prohibition of cannabis by outwitting a regulatory process run by the Home Office and the Medicines and Healthcare Products Regulatory Agency (MHRA) that is corrupt, dishonest and denies scientific evidence. In my view, he deserves great admiration and should be seen as a hero by cannabis campaigners, not as the villain that he is often portrayed.
Now, both GW’s lead products, Sativex and Epidiolex, look set to gain FDA approval in the US. This will be a fantastic achievement for Dr Guy and all his colleagues. It’s also something that we Britons should be immensely proud about. Even though America is a very long way ahead of us in understanding and using cannabis as medicine, it is British science and expertise that is breaking down US federal prohibition. Soon most Americans will have state sanctioned access to medical marijuana but also the option for doctor-prescribed cannabinoid medicine of unparalleled quality and consistency.
Of course, for now GW Pharma stands against the use of raw herbal cannabis and at present that’s a rational business decision but I won’t be at all surprised if in future it moves into that market too. There are already unconfirmed rumours that GW is considering entering the CBD market.
This is a story of enormous courage, innovation and triumph against all the odds. It is in the finest tradition of British ingenuity and business skill. Since the Middle Ages we have led the world in engineering, science and technology. Geoffrey Guy is another world leader from Britain, this small island that has given birth to so many. Surely, at least a knighthood, possibly a Nobel prize must be coming his way soon. Even if the curmudgeonly, loud mouthed critics of today attack him, in future years he will be seen as a great pioneer of medicine and he will deserve his place in history.
Peter Reynolds 